These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

253 related articles for article (PubMed ID: 30917892)

  • 1. Medicines reclassification from a pharmaceutical industry perspective: An international qualitative study.
    Gauld NJ; Kelly FS; Emmerton LM; Kurosawa N; Bryant LJM; Buetow SA
    Res Social Adm Pharm; 2019 Apr; 15(4):387-394. PubMed ID: 30917892
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Analysing the landscape for prescription to non-prescription reclassification (switch) in Germany: an interview study of committee members and stakeholders.
    Gauld NJ
    BMC Health Serv Res; 2019 Jun; 19(1):404. PubMed ID: 31221154
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Widening consumer access to medicines: a comparison of prescription to non-prescription medicine switch in Australia and New Zealand.
    Gauld NJ; Kelly FS; Emmerton LM; Buetow SA
    PLoS One; 2015; 10(3):e0119011. PubMed ID: 25785589
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Australian pharmacy perspectives on increasing access to medicines through reclassification.
    Mey A; King M; Kelly F; Grant G; Townshend J; Baumann-Birkbeck L; Woods P; Hope D
    J Health Serv Res Policy; 2019 Apr; 24(2):81-90. PubMed ID: 30352516
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Why does increasing public access to medicines differ between countries? Qualitative comparison of nine countries.
    Gauld N; Bryant L; Emmerton L; Kelly F; Kurosawa N; Buetow S
    J Health Serv Res Policy; 2015 Oct; 20(4):231-9. PubMed ID: 26152909
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Barriers to positive policy change that aims to increase access to medicines through reclassification: the case of oseltamivir in New Zealand.
    Shaw JP; Gauld N; Kelly F
    Int J Pharm Pract; 2016 Feb; 24(1):6-12. PubMed ID: 26154432
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Widening consumer access to medicines through switching medicines to non-prescription: a six country comparison.
    Gauld NJ; Kelly FS; Kurosawa N; Bryant LJ; Emmerton LM; Buetow SA
    PLoS One; 2014; 9(9):e107726. PubMed ID: 25251434
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Australian pharmacists: ready for increased non-prescription medicines reclassification.
    Hope DL; Woods P; Mey A; Kelly FS; Townshend J; Baumann-Birkbeck LM; King MA
    Int J Pharm Pract; 2020 Jun; 28(3):246-254. PubMed ID: 31913550
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A new model of prescription to nonprescription reclassification: the calcipotriol case study.
    Gauld N; Emmerton L; Kelly F; Buetow S
    Clin Ther; 2012 Jun; 34(6):1324-32. PubMed ID: 22578311
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Early achievements of the Danish pharmaceutical industry--8. Lundbeck].
    Grevsen JV; Kirkegaard H; Kruse E; Kruse PR
    Theriaca; 2016; (43):9-61. PubMed ID: 27491172
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Non-prescription medicines: current issues in Australian community pharmacy.
    Tan AC; Emmerton L
    Int J Pharm Pract; 2009 Aug; 17(4):207-13. PubMed ID: 20217945
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Community pharmacists' adoption of medicines reclassified from prescription-only status: a systematic review of factors associated with decision making.
    Paudyal V; Hansford D; Cunningham S; Stewart D
    Pharmacoepidemiol Drug Saf; 2012 Apr; 21(4):396-406. PubMed ID: 22362493
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The use of non-prescription medicines during lactation: A qualitative study of community pharmacists' attitudes and perspectives.
    Sim TF; Hattingh HL; Sherriff J; Tee LBG
    Res Social Adm Pharm; 2018 May; 14(5):464-470. PubMed ID: 28624292
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pharmacists' adoption into practice of newly reclassified medicines from diverse therapeutic areas in Scotland: a quantitative study of factors associated with decision-making.
    Paudyal V; Hansford D; Cunningham S; Stewart D
    Res Social Adm Pharm; 2014; 10(1):88-105. PubMed ID: 23665077
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pharmaceutical company influences on medication prescribing and their potential impact on quality use of medicines.
    Kyle GJ; Nissen LM; Tett SE
    J Clin Pharm Ther; 2008 Oct; 33(5):553-9. PubMed ID: 18834371
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Do market components account for higher US prescription prices?
    Monaghan MJ; Monaghan MS
    Ann Pharmacother; 1996 Dec; 30(12):1489-94. PubMed ID: 8968463
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Pharmacy Medicines Not Subject to Medical Prescription in Portugal: An Underused Access Opportunity?].
    Martins AP; Gonçalves E; Marcelo A; Vilão S; Aranda Silva J
    Acta Med Port; 2016 Sep; 29(9):542-548. PubMed ID: 28060692
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cost-Effectiveness of Reclassifying Triptans in Australia: Application of an Economic Evaluation Approach to Regulatory Decisions.
    Parkinson B; Gumbie M; Cutler H; Gauld N; Mumford V; Haywood P
    Value Health; 2019 Mar; 22(3):293-302. PubMed ID: 30832967
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Institutional barriers and enablers to implementing and complying with internationally accepted quality standards in the local pharmaceutical industry of Pakistan: a qualitative study.
    Tauqeer F; Myhr K; Gopinathan U
    Health Policy Plan; 2019 Jul; 34(6):440-449. PubMed ID: 31302684
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pharmaceutical counseling: Between evidence-based medicine and profits.
    Egorova SN; Akhmetova T
    Int J Risk Saf Med; 2015; 27 Suppl 1():S87-8. PubMed ID: 26639727
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.